NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175)

Please sign and return to:

Nicola [redacted] Technology Appraisal Administrator
Email: TAComm[redacted]@nice.org.uk
Fax: +44 (0)20 7061 9763
Post: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by Royal College of Physicians and consequently I will not be submitting a personal statement.

Name: Dr Summers

Signed [redacted]

Date:21/8/13

22/Aug/2013 08:20:19 The Christie 0161 4463299 5/5